GoldenGolden
Greffex

Greffex

Gene therapy and vaccine delivery company based in Houstin, TX.

Greffex has 14 vaccines in its portfolio as well as gene therapies in development for conditions such as Hemophila A and Usher Syndrome. The company is developing immune tissue engineering to overcome transplant rejection. Greffex received $18.9 million from the National Institute of Allergy and Infectious Diseases in 2019 for development of its GreVac™ Plug-And-Play technology which expedites production of vaccine candidates for biodefense and infectious diseases. Using Greffex’s universal vaccine platform the company has 12 vaccines in the pipeline including influenza, MERS-CoV, Anthrax, Ebola, tetravalent Dengue and Zika.

Greffex is developing a COVID-19 vaccine that uses an adenovirus vector with a part of the genetic sequence of COVID-19 to cause the body to form an immune response.

Timeline

People

Name
Role
LinkedIn

John Price

President, CEO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.